Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04651088 · ClinicalTrials.gov registry record · Early Phase 1
Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet
A Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT04651088 is a Early Phase 1 study that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 15 participants.
The verdict
NCT04651088, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to compare over the counter and alternative prescription urinary alkalinizing agents to slow release potassium citrate in their ability to modify urinary parameters associated with stone formation.
Interventions
- DRUG Sodium bicarbonate
- DRUG Potassium citrate
- DIETARY_SUPPLEMENT Litholyte
- DIETARY_SUPPLEMENT Crystal Lite
- DRUG Potassium Bicarbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2027-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04651088
The ClinicalTrials.gov registry entry for NCT04651088 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Sodium bicarbonate is the first listed.
NCT04651088 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04651088 about?
NCT04651088 is a clinical study titled "Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet". The purpose of this study is to compare over the counter and alternative prescription urinary alkalinizing agents to slow release potassium citrate in their ability to modify urinary parameters associated with stone formation.
What is the current status of trial NCT04651088?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2026-07-01. Estimated completion is 2027-07.
What interventions are being tested in trial NCT04651088?
The interventions under investigation include: Sodium bicarbonate (DRUG), Potassium citrate (DRUG), Litholyte (DIETARY_SUPPLEMENT), Crystal Lite (DIETARY_SUPPLEMENT), Potassium Bicarbonate (DRUG).
Who is sponsoring clinical trial NCT04651088?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.